Journey Medical Q3 revenue down 18% to $16.1M; net loss $10.1M; DFD-29 Phase 3 75% enrolled

Journey Medical Corp

2022-Q3 EPS reported -$1.09 revenue$57,703,000

Revenue $16.1M in Q3 2022 versus $19.6M in Q3 2021, decline due to Targadox generic competition.
Net loss $10.1M ($0.57/sh) vs $10.6M ($1.16/sh); Non-GAAP Adj EBITDA loss $4.0M vs +$1.3M.
DFD-29 Phase 3 studies 75% enrolled; top-line data expected H1 2023, NDA filing H2 2023.
Nine-month revenue up 26% to $57.7M; CEO expects record full-year 2022 revenue.
Company expects to launch another product in the upcoming months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Journey Medical Corp reported the third quarter and nine months ended September 30, 2022 results: revenue $16.1 million, net income ($10.1) million, EPS ($0.57) per share basic and diluted.

Period: the third quarter and nine months ended September 30, 2022
Revenue: $16.1 million
Net income: ($10.1) million
EPS: ($0.57) per share basic and diluted
Result: reported results

Exact text from the filing

position Journey Medical for sales growth in the coming years. Journey Medical also expects to launch another product in the upcoming months.” Financial Results: · Revenues were $16.1 million for the third quarter of 2022, compared to revenues of $19.6 million for the third quarter of 2021, representing a decline of $3.5 million. The decline in revenue was

View on SEC.gov

Browse all earnings releases →

Journey Medical Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-117116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.